You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Indoor Formaldehyde Detection by a Low-Cost Chemical Sensor Based on Organic Nanofibers

    SBC: Vaporsens, Inc.            Topic: 16NCER1A

    Need: People are exposed to formaldehyde, a carcinogen found in building materials. Highly sensitive, real-time formaldehyde sensors would improve human safety by alerting users to harmful concentrations. _x000D_ _x000D_ Technical Feasibility: Vaporsens produces chemical sensors based on novel organic nanofiber technology. Phase 1 results demonstrated high selectivity, rapid-response time, and dem ...

    SBIR Phase II 2018 Environmental Protection Agency
  2. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Approximatelymillion Americans suffer from asthmawhich leads to aboutdeaths per yearand is responsible for estimated annual total direct and indirect costs of $billionDespite the existing treatments for asthmapredominantly combinations of inhaledagonists and corticosteroidsCSsthere remains a significant unmet medical need for new therapies which address two key issuesapproximatelyof patients are i ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Biodegradable Vascular Coupling Device for End-to-End Anastomosis

    SBC: Microsurgical Innovations Inc            Topic: NHLBI

    Project Summary The objective of Microsurgical InnovationsMSIin this proposal is to develop a biodegradable vascular coupling deviceVCDwhich would replace the hand suturing technique currently used to connect arteries and veins in microvascular and macrovascular end to end vascular repair surgeriesOur device works for both arteries and veins and can rapidly connect the two vessel ends together in ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    SBC: Recursion Pharmaceuticals, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The pla ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. IOBIO based, distributed genomic data access, management, visualization, and analysis

    SBC: FRAMESHIFT LABS INC            Topic: 172

    The precision medicine initiative coupled with advances in genomic research and diagnostics isleading to vast increases in the volume of genomic data being createdwith some estimates statingit will outstrip the storage requirements of YouTube byEnsuring all this data can becost effectively managedand that experts from the biomedicalinformatics and medical disciplinescan easily collaborate on analy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government